• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Oral anticoagulation in device-detected atrial fibrillation: effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes in the NOAH-AFNET 6 trial.

作者信息

Lip Gregory Y H, Nikorowitsch Julius, Sehner Susanne, Becher Nina, Bertaglia Emanuele, Blomstrom-Lundqvist Carina, Brandes Axel, Beuger Vincent, Calvert Melanie, Camm A John, Chlouverakis Gregory, Dan Gheorghe-Andrei, Dichtl Wolfgang, Diener Hans Christoph, Fierenz Alexander, Goette Andreas, de Groot Joris R, Hermans Astrid, Lubinski Andrzej, Marijon Eloi, Merkely Béla, Mont Lluís, Ozga Ann-Kathrin, Rajappan Kim, Sarkozy Andrea, Scherr Daniel, Schnabel Renate B, Schotten Ulrich, Simantirakis Emmanuel, Toennis Tobias, Vardas Panos, Wichterle Dan, Zapf Antonia, Kirchhof Paulus

机构信息

Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK.

Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

出版信息

Eur Heart J. 2024 May 21;45(19):1733-1737. doi: 10.1093/eurheartj/ehae225.

DOI:10.1093/eurheartj/ehae225
PMID:38591192
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11107119/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a757/11107119/31bfba31702c/ehae225f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a757/11107119/31bfba31702c/ehae225f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a757/11107119/31bfba31702c/ehae225f1.jpg

相似文献

1
Oral anticoagulation in device-detected atrial fibrillation: effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes in the NOAH-AFNET 6 trial.装置检测到的心房颤动患者的口服抗凝治疗：年龄、性别、心血管合并症及肾功能对NOAH-AFNET 6试验结局的影响
Eur Heart J. 2024 May 21;45(19):1733-1737. doi: 10.1093/eurheartj/ehae225.
2
Anticoagulation in Patients With Device-Detected Atrial Fibrillation With and Without a Prior Stroke or Transient Ischemic Attack: The NOAH-AFNET 6 Trial.伴有或不伴有既往卒中和短暂性脑缺血发作的器械检出心房颤动患者的抗凝治疗：NOAH-AFNET 6 试验。
J Am Heart Assoc. 2024 Sep 3;13(17):e036429. doi: 10.1161/JAHA.124.036429. Epub 2024 Aug 27.
3
Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial.探索心房高率发作患者的口服抗凝治疗：心房高率发作患者非维生素K拮抗剂口服抗凝剂（NOAH-AFNET 6）试验的原理与设计
Am Heart J. 2017 Aug;190:12-18. doi: 10.1016/j.ahj.2017.04.015. Epub 2017 May 3.
4
Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials.直接口服抗凝剂预防器械检测到的心房颤动患者卒中：NOAH-AFNET 6 和 ARTESiA 试验的研究水平荟萃分析。
Circulation. 2024 Mar 26;149(13):981-988. doi: 10.1161/CIRCULATIONAHA.123.067512. Epub 2023 Nov 12.
5
When to prescribe oral anticoagulation for patients with device-detected subclinical atrial fibrillation? Insights from the NOAH-AFNET 6 and ARTESiA trials.何时应为设备检测到的亚临床房颤患者开具口服抗凝药？来自NOAH-AFNET 6和ARTESiA试验的见解。
Eur J Intern Med. 2024 May;123:52-54. doi: 10.1016/j.ejim.2024.03.031. Epub 2024 Apr 9.
6
Anticoagulation with edoxaban in patients with long atrial high-rate episodes ≥24 h.在心房高率事件持续时间≥24 h 的患者中使用依度沙班进行抗凝治疗。
Eur Heart J. 2024 Mar 7;45(10):837-849. doi: 10.1093/eurheartj/ehad771.
7
Letter by Aldaas et al Regarding Article, "Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials".阿尔达斯等人就“器械检测到的心房颤动患者预防卒中的直接口服抗凝剂：NOAH-AFNET 6和ARTESiA试验的研究水平荟萃分析”一文所写的信。
Circulation. 2024 Oct 8;150(15):e273. doi: 10.1161/CIRCULATIONAHA.123.068081. Epub 2024 Oct 7.
8
Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation.CHA2DS2-VASc 评分对房颤抗凝推荐的影响。
Am J Med. 2012 Jun;125(6):603.e1-6. doi: 10.1016/j.amjmed.2011.09.030. Epub 2012 Apr 11.
9
Oral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor: The Loire Valley Atrial Fibrillation Project.口服抗凝药与伴有 1 项以上卒中危险因素的心房颤动患者卒中或死亡的风险：卢瓦尔河谷心房颤动项目。
Chest. 2016 Apr;149(4):960-8. doi: 10.1378/chest.15-1622. Epub 2016 Jan 12.
10
Is an Oral Anticoagulant Necessary for Young Atrial Fibrillation Patients With a CHA2DS2-VASc Score of 1 (Men) or 2 (Women)?CHA2DS2-VASc评分为1（男性）或2（女性）的年轻房颤患者是否需要口服抗凝药？
J Am Heart Assoc. 2016 Oct 4;5(10):e003839. doi: 10.1161/JAHA.116.003839.

引用本文的文献

1
Net Benefit of Anticoagulation in Subclinical Device-Detected Atrial Fibrillation.亚临床设备检测到的心房颤动中抗凝治疗的净效益
JAMA Netw Open. 2025 May 1;8(5):e258461. doi: 10.1001/jamanetworkopen.2025.8461.
2
Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials.有或无血管疾病的器械检测到的心房颤动的抗凝治疗：NOAH-AFNET 6和ARTESiA试验的联合分析
Eur Heart J. 2024 Dec 7;45(46):4902-4916. doi: 10.1093/eurheartj/ehae596.
3
Atrial fibrillation burden: a new outcome predictor and therapeutic target.

本文引用的文献

1
Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials.直接口服抗凝剂预防器械检测到的心房颤动患者卒中：NOAH-AFNET 6 和 ARTESiA 试验的研究水平荟萃分析。
Circulation. 2024 Mar 26;149(13):981-988. doi: 10.1161/CIRCULATIONAHA.123.067512. Epub 2023 Nov 12.
2
Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation.阿哌沙班预防非瓣膜性心房颤动的卒中。
N Engl J Med. 2024 Jan 11;390(2):107-117. doi: 10.1056/NEJMoa2310234. Epub 2023 Nov 12.
3
Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes.
房颤负担：一个新的预后预测因子和治疗靶点。
Eur Heart J. 2024 Aug 16;45(31):2824-2838. doi: 10.1093/eurheartj/ehae373.
在伴有心房快速发作的患者中使用依度沙班进行抗凝治疗。
N Engl J Med. 2023 Sep 28;389(13):1167-1179. doi: 10.1056/NEJMoa2303062. Epub 2023 Aug 25.
4
Attaining sinus rhythm mediates improved outcome with early rhythm control therapy of atrial fibrillation: the EAST-AFNET 4 trial.实现窦律可改善房颤早期节律控制治疗的预后：EAST-AFNET 4 试验。
Eur Heart J. 2022 Oct 21;43(40):4127-4144. doi: 10.1093/eurheartj/ehac471.
5
Early Rhythm-Control Therapy in Patients with Atrial Fibrillation.心房颤动患者的早期节律控制治疗。
N Engl J Med. 2020 Oct 1;383(14):1305-1316. doi: 10.1056/NEJMoa2019422. Epub 2020 Aug 29.
6
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.2020年欧洲心脏病学会（ESC）与欧洲心胸外科学会（EACTS）合作制定的心房颤动诊断和管理指南：欧洲心脏病学会（ESC）心房颤动诊断和管理特别工作组，由ESC欧洲心律协会（EHRA）特别贡献制定。
Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612.
7
Natural History of Subclinical Atrial Fibrillation Detected by Implanted Loop Recorders.植入式环路记录器检测到的无症状心房颤动的自然史。
J Am Coll Cardiol. 2019 Dec 3;74(22):2771-2781. doi: 10.1016/j.jacc.2019.09.050.
8
Stroke Risk as a Function of Atrial Fibrillation Duration and CHADS-VASc Score.房颤持续时间和 CHADS-VASc 评分与卒中风险的关系。
Circulation. 2019 Nov 12;140(20):1639-1646. doi: 10.1161/CIRCULATIONAHA.119.041303. Epub 2019 Sep 30.
9
Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES.根据房颤模式评估缺血性卒中风险：ACTIVE-A 和 AVERROES 中 6563 例阿司匹林治疗患者的分析。
Eur Heart J. 2015 Feb 1;36(5):281-7a. doi: 10.1093/eurheartj/ehu307. Epub 2014 Sep 3.